Literature DB >> 10022640

Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease.

B I Korelitz1, S R Fuller, J I Warman, M D Goldberg.   

Abstract

OBJECTIVE: Our aim was to study the frequency, severity, and outcome of patients with Crohn's disease and ulcerative colitis treated with 6-mercaptopurine (6MP) who developed shingles during treatment, and to recommend management. While varicella can be severe in young people immunocompromised by steroids, the incidence of herpes zoster in older people with inflammatory bowel disease (IBD) and whether its severity is influenced by 6MP and azathioprine are unknown.
METHODS: Data were collected from our IBD Center on 550 patients with IBD to identify those who developed shingles while on 6MP, its severity, the dose and duration of 6MP, and the management of the 6MP.
RESULTS: Twelve of 550 patients with IBD treated with 6MP developed shingles. In two with herpes zoster ophthalmicus the pain was prolonged, and one patient developed encephalitis which was brief and uncomplicated; in nine patients the course was benign. Acyclovir should be the treatment of choice even though it was available in only three cases.
CONCLUSIONS: Shingles occurs more often in IBD patients treated with 6MP than in those who are not, but the course is usually benign and there has been no mortality. The 6MP should be stopped temporarily until severity is established but if the underlying disease warrants further treatment the 6MP should be restarted.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022640     DOI: 10.1111/j.1572-0241.1999.871_w.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

1.  Herpes simplex virus encephalistis during immunosuppressive treatment of ulcerative colitis.

Authors:  Seyed Meysam Alimohamadi; Reza Malekzadeh; Seyed Hossein Mirmadjless; Mehdi Mohamadnejad; Farhad Zamani
Journal:  MedGenMed       Date:  2004-11-10

2.  Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations.

Authors:  James D Lewis; Oren Abramson; Monina Pascua; Liyan Liu; Laura M Asakura; Fernando S Velayos; Susan M Hutfless; James E Alison; Lisa J Herrinton
Journal:  Clin Gastroenterol Hepatol       Date:  2009-07-22       Impact factor: 11.382

3.  IBD: incidence of HSV and HPV with azathioprine.

Authors:  Mario Cottone; Sara Renna
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-08       Impact factor: 46.802

Review 4.  Long-term safety of immunomodulators in pediatric inflammatory diseases.

Authors:  Federica Nuti; Fortunata Civitelli; Salvatore Cucchiara
Journal:  Paediatr Drugs       Date:  2014-10       Impact factor: 3.022

5.  Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines.

Authors:  Iris Dotan; Lael Werner; Sharon Vigodman; Shradha Agarwal; Jorge Pfeffer; Noya Horowitz; Lisa Malter; Maria Abreu; Thomas Ullman; Hanan Guzner-Gur; Zamir Halpern; Lloyd Mayer
Journal:  Inflamm Bowel Dis       Date:  2011-03-15       Impact factor: 5.325

6.  Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants.

Authors:  G Andrisani; D Frasca; M Romero; A Armuzzi; C Felice; M Marzo; D Pugliese; A Papa; G Mocci; I De Vitis; G L Rapaccini; B B Blomberg; L Guidi
Journal:  J Crohns Colitis       Date:  2012-06-05       Impact factor: 9.071

7.  Immune response to influenza vaccine in children with inflammatory bowel disease.

Authors:  Ying Lu; Denise L Jacobson; Lori A Ashworth; Richard J Grand; Anthony L Meyer; Monica M McNeal; Matt C Gregas; Sandra K Burchett; Athos Bousvaros
Journal:  Am J Gastroenterol       Date:  2009-01-27       Impact factor: 10.864

8.  Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy.

Authors:  Ying Lu; Athos Bousvaros
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-06

9.  AID in aging and autoimmune diseases.

Authors:  Daniela Frasca; Gianluca Andrisani; Alain Diaz; Carla Felice; Luisa Guidi; Bonnie B Blomberg
Journal:  Autoimmunity       Date:  2013-03       Impact factor: 2.815

10.  Risk Factors for Aseptic Meningitis in Herpes Zoster Patients.

Authors:  Sang-Hoon Kim; Seong-Min Choi; Byeong C Kim; Kang-Ho Choi; Tai-Seung Nam; Joon-Tae Kim; Seung-Han Lee; Man-Seok Park; Seong J Kim
Journal:  Ann Dermatol       Date:  2017-05-11       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.